FDA Pharmacogenomics Guide Needs Process To Accept Biomarkers – PhRMA

FDA should define a process to prospectively validate biomarkers for pharmacogenomic product approval, the Pharmaceutical Research & Manufacturers of America said in comments on an FDA draft guidance

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet